BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

GlobeNewswire05-19 20:00

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.

Fireside Chat Details:

Time: 11:40 AM ET
Date: Wednesday, May 20, 2026

Investors can register for the conference and view the fireside chat here.

About BioCardia^®

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP^® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph^® vascular navigation product platforms. For more information visit: www.BioCardia.com.

CONTACT: Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636855228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636855228","market":"sh","top_or_hot":-1,"title":"BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase","media":"GlobeNewswire","content":"<html><body><p>SUNNYVALE, Calif., May  19, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BCDA\">BioCardia</a>, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.</p> <p>Fireside Chat Details:</p> <ul type=\"disc\"><li>Time: 11:40 AM ET</li><li>Date: Wednesday, May 20, 2026</li></ul> <p>Investors can register for the conference and view the fireside chat here.</p> <p><strong>About BioCardia<sup>®</sup></strong></p> <p>BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP<sup>®</sup> autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™<strong> </strong>biotherapeutic delivery and Morph<sup>®</sup> vascular navigation product platforms. For more information visit: www.BioCardia.com.</p> <pre>CONTACT: Media Contact:\nMiranda Peto, Investor Relations\nEmail: mpeto@BioCardia.com\nPhone: 650-226-0120\n\nInvestor Contact:\nDavid McClung, Chief Financial Officer\nEmail: investors@BioCardia.com\nPhone: 650-226-0120</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MmJlMjNlNDgtOTIzMi00MGE5LWI2NDAtZDI5OTk0MjczZmEzLTEwMzEzOTEtMjAyNi0wNS0xOS1lbg==/tiny/BioCardia-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-05-19 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>SUNNYVALE, Calif., May  19, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BCDA\">BioCardia</a>, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.</p> <p>Fireside Chat Details:</p> <ul type=\"disc\"><li>Time: 11:40 AM ET</li><li>Date: Wednesday, May 20, 2026</li></ul> <p>Investors can register for the conference and view the fireside chat here.</p> <p><strong>About BioCardia<sup>®</sup></strong></p> <p>BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP<sup>®</sup> autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™<strong> </strong>biotherapeutic delivery and Morph<sup>®</sup> vascular navigation product platforms. For more information visit: www.BioCardia.com.</p> <pre>CONTACT: Media Contact:\nMiranda Peto, Investor Relations\nEmail: mpeto@BioCardia.com\nPhone: 650-226-0120\n\nInvestor Contact:\nDavid McClung, Chief Financial Officer\nEmail: investors@BioCardia.com\nPhone: 650-226-0120</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MmJlMjNlNDgtOTIzMi00MGE5LWI2NDAtZDI5OTk0MjczZmEzLTEwMzEzOTEtMjAyNi0wNS0xOS1lbg==/tiny/BioCardia-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128526141.USD","symbol_name":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297421/0/en/BioCardia-to-Participate-in-a-Fireside-Chat-at-the-Alliance-Global-Partners-A-G-P-Healthcare-Company-Showcase.html","article_id":"2636855228","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636855228","pubTimestamp":1779192000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Miranda Peto, Investor Relations. Email: mpeto@BioCardia.com. Phone: 650-226-0120. Investor Contact:. David McClung, Chief Financial Officer. Email: investors@BioCardia.com. Phone: 650-226-0120","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","XLV":"健康照护类股ETF-SPDR","XBI":"SPDR S&P Biotech ETF","BK4581":"高盛持仓","BK4585":"ETF&股票定投概念","BCDA":"BioCardia","BK4137":"综合支持服务","LABU":"三倍做多标普生物-Direxion","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4588":"碎股","HCSG":"Healthcare Svcs Group Inc","BK4139":"生物科技"},"translate_title":"BioCardia将参加Alliance Global Partners(A.G.P)医疗保健公司展示的炉边谈话","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCDA":1.5,"LABU":0.6,"XBI":0.6,"HCSG":1.5,"XLV":1.5},"content_text":"SUNNYVALE, Calif., May  19, 2026  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase. Fireside Chat Details: Time: 11:40 AM ETDate: Wednesday, May 20, 2026 Investors can register for the conference and view the fireside chat here. About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: www.BioCardia.com. CONTACT: Media Contact:\nMiranda Peto, Investor Relations\nEmail: mpeto@BioCardia.com\nPhone: 650-226-0120\n\nInvestor Contact:\nDavid McClung, Chief Financial Officer\nEmail: investors@BioCardia.com\nPhone: 650-226-0120","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636855228","isCrawlerRequest":true}